RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis
Zacks Investment Research | Sep 07, 2021 10:29PM ET
RedHill Biopharma (NASDAQ:RDHL) industry ’s 9.6% decline.
Image Source: Zacks Investment Research
In CKD patients, renal fibrosis is a progressive process that may result in end-stage renal failure. COVID-19 and long COVID patients also have a high risk of kidney damage.
More than 20% of hospitalized COVID patients experience acute renal failure. Acute kidney injury –- a potential consequence of COVID-19 –- results in the inability of the kidneys to be repaired properly. Opaganib inhibits the sphingosine kinase-2, a key enzyme that is part of the process that prevents the kidney from repairing itself and replicating the COVID-19 virus.
It is to be noted that Opaganib, an oral pill drug candidate with dual anti-inflammatory and antiviral activity, is currently being evaluated in a phase II/III study in hospitalized patients with COVID-19. This study has completed treatment and follow up phase, with top-line results expected shortly.
The company recently announced positive preliminary results from a new preclinical study on Opaganib. The drug demonstrated strong inhibition of delta variant of the COVID virus in a human bronchial epithelial cells model, adding to prior data demonstrating potent inhibition of all COVID-19 variants tested to date.
Ironwood’s earnings per share estimates for 2021 have increased from $1.00 to $1.18 in the past 60 days. The same for 2022 has risen from $1.18 to $1.72 over the same period. The stock has rallied 10.3% in the year so far.
Regeneron’s earnings per share estimates for 2021 have increased from $49.51 to $54.15 in the past 60 days. The same for 2022 has risen from $41.30 to $44.11 over the same period. The stock has rallied 38.4% in the year so far.
Repligen’s earnings per share estimates for 2021 have increased from $2.26 to $2.76 in the past 60 days. The same for 2022 has risen from $2.56 to $3.02 over the same period. The stock has rallied 54.6% in the year so far.
Zacks’ Top Picks to Cash in on Artificial Intelligence
This world-changing technology is projected to generate $100s of billions by 2025. From self-driving cars to consumer data analysis, people are relying on machines more than we ever have before. Now is the time to capitalize on the 4th Industrial Revolution. Zacks’ urgent special report reveals 6 AI picks investors need to know about today.
See 6 Artificial Intelligence Stocks With Extreme Upside Potential>>
Get The News You Want
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.